US20020164782A1
(en)
|
1999-02-10 |
2002-11-07 |
Gregory Richard J. |
Adenovirus vectors for gene therapy
|
US5670488A
(en)
*
|
1992-12-03 |
1997-09-23 |
Genzyme Corporation |
Adenovirus vector for gene therapy
|
US8153602B1
(en)
*
|
1991-11-19 |
2012-04-10 |
Isis Pharmaceuticals, Inc. |
Composition and methods for the pulmonary delivery of nucleic acids
|
US5795870A
(en)
*
|
1991-12-13 |
1998-08-18 |
Trustees Of Princeton University |
Compositions and methods for cell transformation
|
US5693769A
(en)
*
|
1991-12-13 |
1997-12-02 |
Transcell Technologies, Inc. |
Glycosylated steroid derivatives for transport across biological membranes and process for making and using same
|
US5858784A
(en)
*
|
1991-12-17 |
1999-01-12 |
The Regents Of The University Of California |
Expression of cloned genes in the lung by aerosol- and liposome-based delivery
|
WO1993012240A1
(en)
*
|
1991-12-17 |
1993-06-24 |
The Regents Of The University Of California |
Gene therapy for cystic fibrosis transmembrane conductance regulator activity (cftr)
|
WO1994005782A1
(en)
*
|
1992-09-10 |
1994-03-17 |
Trustees Of Tufts College |
In vivo production of transgenic organ by introducing the transgene via lumen
|
WO1994027435A1
(en)
|
1993-06-01 |
1994-12-08 |
Life Technologies, Inc. |
Genetic immunization with cationic lipids
|
US5688677A
(en)
*
|
1993-10-13 |
1997-11-18 |
Genzyme Corporation |
Deoxyribonucleic acids containing inactivated hormone responsive elements
|
WO1995010538A1
(en)
*
|
1993-10-15 |
1995-04-20 |
The University Of North Carolina At Chapel Hill |
Dna encoding the human p2u receptor and null cells expressing p2u receptors
|
US6887856B1
(en)
|
1993-10-15 |
2005-05-03 |
University Of Pittsburgh |
Protection from ionizing irradiation or chemotherapeutic drug damage by in vivo gene therapy
|
FR2711523B1
(fr)
|
1993-10-26 |
1996-02-16 |
Transgene Sa |
Procédé de préparation d'un aérosol viral.
|
US5614551A
(en)
*
|
1994-01-24 |
1997-03-25 |
The Johns Hopkins University |
Inhibitors of fatty acid synthesis as antimicrobial agents
|
US6995008B1
(en)
|
1994-03-07 |
2006-02-07 |
Merck & Co., Inc. |
Coordinate in vivo gene expression
|
US5670347A
(en)
|
1994-05-11 |
1997-09-23 |
Amba Biosciences Llc |
Peptide-mediated gene transfer
|
US6207646B1
(en)
*
|
1994-07-15 |
2001-03-27 |
University Of Iowa Research Foundation |
Immunostimulatory nucleic acid molecules
|
US20030026782A1
(en)
*
|
1995-02-07 |
2003-02-06 |
Arthur M. Krieg |
Immunomodulatory oligonucleotides
|
AUPM747694A0
(en)
*
|
1994-08-16 |
1994-09-08 |
Commonwealth Scientific And Industrial Research Organisation |
Delivery of nucleic acids and peptides
|
FR2727679B1
(fr)
*
|
1994-12-05 |
1997-01-03 |
Rhone Poulenc Rorer Sa |
Nouveaux agents de transfection et leurs applications pharmaceutiques
|
US6383814B1
(en)
*
|
1994-12-09 |
2002-05-07 |
Genzyme Corporation |
Cationic amphiphiles for intracellular delivery of therapeutic molecules
|
US6472374B1
(en)
*
|
1994-12-24 |
2002-10-29 |
Cambridge University Technical Services Limited |
Endometrial function
|
US5795587A
(en)
*
|
1995-01-23 |
1998-08-18 |
University Of Pittsburgh |
Stable lipid-comprising drug delivery complexes and methods for their production
|
US6008202A
(en)
*
|
1995-01-23 |
1999-12-28 |
University Of Pittsburgh |
Stable lipid-comprising drug delivery complexes and methods for their production
|
FR2732895B1
(fr)
*
|
1995-04-11 |
1997-05-16 |
Pasteur Merieux Serums Vacc |
Utilisation d'un compose amphipathique cationique comme agent de transfection, comme adjuvant de vaccin, ou comme medicament
|
US5935568A
(en)
*
|
1995-05-18 |
1999-08-10 |
National Jewish Medical & Research Center |
Gene therapy for effector cell regulation
|
US7034007B1
(en)
|
1995-06-07 |
2006-04-25 |
East Carolina University |
Low adenosine anti-sense oligonucleotide, compositions, kit & method for treatment of airway disorders associated with bronchoconstriction, lung inflammation, allergy(ies) & surfactant depletion
|
US5756122A
(en)
*
|
1995-06-07 |
1998-05-26 |
Georgetown University |
Liposomally encapsulated nucleic acids having high entrapment efficiencies, method of manufacturer and use thereof for transfection of targeted cells
|
US5994315A
(en)
*
|
1995-06-07 |
1999-11-30 |
East Carolina University |
Low adenosine agent, composition, kit and method for treatment of airway disease
|
US5981501A
(en)
*
|
1995-06-07 |
1999-11-09 |
Inex Pharmaceuticals Corp. |
Methods for encapsulating plasmids in lipid bilayers
|
US7422902B1
(en)
|
1995-06-07 |
2008-09-09 |
The University Of British Columbia |
Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
|
DE69634084T2
(de)
*
|
1995-06-07 |
2005-12-08 |
Inex Pharmaceuticals Corp. |
Herstellung von lipid-nukleinsäure partikeln duch ein hydrophobische lipid-nukleinsäuree komplexe zwischenprodukt und zur verwendung in der gentransfer
|
US6040296A
(en)
*
|
1995-06-07 |
2000-03-21 |
East Carolina University |
Specific antisense oligonucleotide composition & method for treatment of disorders associated with bronchoconstriction and lung inflammation
|
US6825174B2
(en)
|
1995-06-07 |
2004-11-30 |
East Carolina University |
Composition, formulations & method for prevention & treatment of diseases and conditions associated with bronchoconstriction, allergy(ies) & inflammation
|
AU771241B2
(en)
*
|
1995-06-07 |
2004-03-18 |
Tekmira Pharmaceuticals Corporation |
Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
|
US5705385A
(en)
*
|
1995-06-07 |
1998-01-06 |
Inex Pharmaceuticals Corporation |
Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
|
US6025339A
(en)
*
|
1995-06-07 |
2000-02-15 |
East Carolina University |
Composition, kit and method for treatment of disorders associated with bronchoconstriction and lung inflammation
|
US5869715A
(en)
*
|
1995-09-27 |
1999-02-09 |
The Reagents Of The University Of California |
Polyfunctional cationic cytofectins
|
AU7078396A
(en)
*
|
1995-09-27 |
1997-04-30 |
Regents Of The University Of California, The |
Polyfunctional cationic cytofectins, formulations and methods for generating active cytofectin:polynucleotide transfection complexes
|
US6121247A
(en)
*
|
1996-03-29 |
2000-09-19 |
The Johns Hopkins University |
Therapy for allergic diseases
|
US6156567A
(en)
*
|
1996-07-03 |
2000-12-05 |
Merial |
Truncated transcriptionally active cytomegalovirus promoters
|
JP2001502666A
(ja)
|
1996-09-12 |
2001-02-27 |
ジェネメディシン,インコーポレイテッド |
肺遺伝子送達のための組成物および方法
|
US6977244B2
(en)
*
|
1996-10-04 |
2005-12-20 |
Board Of Regents, The University Of Texas Systems |
Inhibition of Bcl-2 protein expression by liposomal antisense oligodeoxynucleotides
|
CA2269825A1
(en)
|
1996-10-24 |
1998-04-30 |
Kenneth Brigham |
Gene delivery and expression in areas inaccessible to direct protein delivery
|
US6797276B1
(en)
|
1996-11-14 |
2004-09-28 |
The United States Of America As Represented By The Secretary Of The Army |
Use of penetration enhancers and barrier disruption agents to enhance the transcutaneous immune response
|
US20060002949A1
(en)
|
1996-11-14 |
2006-01-05 |
Army Govt. Of The Usa, As Rep. By Secretary Of The Office Of The Command Judge Advocate, Hq Usamrmc. |
Transcutaneous immunization without heterologous adjuvant
|
US5980898A
(en)
*
|
1996-11-14 |
1999-11-09 |
The United States Of America As Represented By The U.S. Army Medical Research & Material Command |
Adjuvant for transcutaneous immunization
|
US20060002959A1
(en)
*
|
1996-11-14 |
2006-01-05 |
Government Of The United States |
Skin-sctive adjuvants for transcutaneous immuization
|
US5981575A
(en)
*
|
1996-11-15 |
1999-11-09 |
Johns Hopkins University, The |
Inhibition of fatty acid synthase as a means to reduce adipocyte mass
|
US6034072A
(en)
*
|
1997-02-10 |
2000-03-07 |
Genemedicine, Inc. |
IL-2 gene expression and delivery systems and uses
|
US5837283A
(en)
|
1997-03-12 |
1998-11-17 |
The Regents Of The University Of California |
Cationic lipid compositions targeting angiogenic endothelial cells
|
US7112338B2
(en)
|
1997-03-12 |
2006-09-26 |
The Regents Of The University Of California |
Cationic liposome delivery of taxanes to angiogenic blood vessels
|
US5965542A
(en)
*
|
1997-03-18 |
1999-10-12 |
Inex Pharmaceuticals Corp. |
Use of temperature to control the size of cationic liposome/plasmid DNA complexes
|
US6126965A
(en)
*
|
1997-03-21 |
2000-10-03 |
Georgetown University School Of Medicine |
Liposomes containing oligonucleotides
|
US6559129B1
(en)
*
|
1997-03-21 |
2003-05-06 |
Georgetown University |
Cationic liposomal delivery system and therapeutic use thereof
|
US7262173B2
(en)
*
|
1997-03-21 |
2007-08-28 |
Georgetown University |
Chemosensitizing with liposomes containing oligonucleotides
|
US20030229040A1
(en)
*
|
1997-03-21 |
2003-12-11 |
Georgetown University |
Cationic liposomal delivery system and therapeutic use thereof
|
US5958894A
(en)
*
|
1997-04-04 |
1999-09-28 |
Megabios Corporation |
Amphiphilic biguanide derivatives
|
US6235310B1
(en)
|
1997-04-04 |
2001-05-22 |
Valentis, Inc. |
Methods of delivery using cationic lipids and helper lipids
|
US5948925A
(en)
*
|
1997-05-06 |
1999-09-07 |
Genzyme Corporation |
Cationic amphiphiles containing linkers derived from neutral or positively charged amino acids
|
US5952516A
(en)
*
|
1997-05-08 |
1999-09-14 |
Genzyme Corporation |
Cationic amphiphiles containing multiplesteroid lipophilic groups
|
US5942634A
(en)
*
|
1997-05-09 |
1999-08-24 |
Genzyme Corporation |
Cationic amphiphiles for cell transfections
|
CA2205076A1
(en)
|
1997-05-14 |
1998-11-14 |
Jim Hu |
Episomal expression cassettes for gene therapy
|
US20090239940A1
(en)
*
|
1997-07-22 |
2009-09-24 |
Del Monte Federica |
Treating heart failure and ventricular arrhythmias
|
US7923250B2
(en)
|
1997-07-30 |
2011-04-12 |
Warsaw Orthopedic, Inc. |
Methods of expressing LIM mineralization protein in non-osseous cells
|
WO1999006563A1
(en)
|
1997-07-30 |
1999-02-11 |
Emory University |
Novel bone mineralization proteins, dna, vectors, expression systems
|
US20050142126A1
(en)
*
|
1997-08-20 |
2005-06-30 |
Bernard Knoops |
Peroxisome-associated polypeptide, nucleotide sequence encoding said polypeptide and their uses in the diagnosis and/or the treatment of lung injuries and diseases, and of oxidative stress-related disorders
|
CA2304983A1
(en)
|
1997-09-24 |
1999-04-01 |
The Regents Of The University Of California |
Non-primate lentiviral vectors and packaging systems
|
US6565885B1
(en)
|
1997-09-29 |
2003-05-20 |
Inhale Therapeutic Systems, Inc. |
Methods of spray drying pharmaceutical compositions
|
US6946117B1
(en)
|
1997-09-29 |
2005-09-20 |
Nektar Therapeutics |
Stabilized preparations for use in nebulizers
|
US20060165606A1
(en)
*
|
1997-09-29 |
2006-07-27 |
Nektar Therapeutics |
Pulmonary delivery particles comprising water insoluble or crystalline active agents
|
US20020017295A1
(en)
*
|
2000-07-07 |
2002-02-14 |
Weers Jeffry G. |
Phospholipid-based powders for inhalation
|
US6309623B1
(en)
|
1997-09-29 |
2001-10-30 |
Inhale Therapeutic Systems, Inc. |
Stabilized preparations for use in metered dose inhalers
|
US6433040B1
(en)
*
|
1997-09-29 |
2002-08-13 |
Inhale Therapeutic Systems, Inc. |
Stabilized bioactive preparations and methods of use
|
US7704962B1
(en)
*
|
1997-10-03 |
2010-04-27 |
Board Of Regents, The University Of Texas System |
Small oligonucleotides with anti-tumor activity
|
US7285288B1
(en)
|
1997-10-03 |
2007-10-23 |
Board Of Regents, The University Of Texas System |
Inhibition of Bcl-2 protein expression by liposomal antisense oligodeoxynucleotides
|
US20040258703A1
(en)
*
|
1997-11-14 |
2004-12-23 |
The Government Of The Us, As Represented By The Secretary Of The Army |
Skin-active adjuvants for transcutaneous immunization
|
US7157098B1
(en)
*
|
1998-01-06 |
2007-01-02 |
Roman Perez-Soler |
Gene therapy of tumors using non-viral delivery system
|
US6375980B1
(en)
*
|
1998-01-08 |
2002-04-23 |
Research Development Foundation |
Stabilization of lipid:DNA formulations during nebulization
|
TW520294B
(en)
*
|
1998-01-08 |
2003-02-11 |
Res Dev Foundation |
Stabilization of lipid: DNA formulations during nebulization
|
US6410328B1
(en)
|
1998-02-03 |
2002-06-25 |
Protiva Biotherapeutics Inc. |
Sensitizing cells to compounds using lipid-mediated gene and compound delivery
|
JP2002502831A
(ja)
|
1998-02-03 |
2002-01-29 |
イネックス ファーマシューティカルズ コーポレイション |
癌の治療に用いる血清に対して安定なプラスミド脂質粒子の全身供与
|
US6158431A
(en)
*
|
1998-02-13 |
2000-12-12 |
Tsi Incorporated |
Portable systems and methods for delivery of therapeutic material to the pulmonary system
|
US6221848B1
(en)
|
1998-05-11 |
2001-04-24 |
University Of Pittsburgh |
Protection of the esophagus from chemotherapeutic or irradiation damage by gene therapy
|
AU4007899A
(en)
*
|
1998-05-21 |
1999-12-06 |
Isis Pharmaceuticals, Inc. |
Compositions and methods for the pulmonary delivery of nucleic acids
|
JP2002515513A
(ja)
*
|
1998-05-21 |
2002-05-28 |
アイシス・ファーマシューティカルス・インコーポレーテッド |
核酸の肺送達のための組成物および方法
|
US20040247662A1
(en)
*
|
1998-06-25 |
2004-12-09 |
Dow Steven W. |
Systemic immune activation method using nucleic acid-lipid complexes
|
US20030022854A1
(en)
*
|
1998-06-25 |
2003-01-30 |
Dow Steven W. |
Vaccines using nucleic acid-lipid complexes
|
US6693086B1
(en)
|
1998-06-25 |
2004-02-17 |
National Jewish Medical And Research Center |
Systemic immune activation method using nucleic acid-lipid complexes
|
AU5337499A
(en)
*
|
1998-08-03 |
2000-03-06 |
East Carolina University |
Low adenosine anti-sense oligonucleotide agent, composition, kit and treatments
|
JP2002529393A
(ja)
*
|
1998-11-12 |
2002-09-10 |
フランク ジー. ピルキーウィッツ, |
吸入システム
|
EP1839648A3
(de)
*
|
1998-11-12 |
2007-11-21 |
Transave, Inc. |
Inhalationssystem
|
DK1129064T3
(da)
|
1998-11-12 |
2008-04-28 |
Invitrogen Corp |
Transfektionsreagenser
|
US6855549B1
(en)
|
1998-11-23 |
2005-02-15 |
The University Of Iowa Research Foundation |
Methods and compositions for increasing the infectivity of gene transfer vectors
|
US6716810B1
(en)
*
|
1998-12-09 |
2004-04-06 |
Eleanor Roosevelt Institute |
Composition and method for regulation of body weight and associated conditions
|
EP1538162B1
(de)
*
|
1999-02-24 |
2012-04-11 |
North Carolina State University |
Verbindungen zur Veränderung der Schleimsekretion
|
US7544772B2
(en)
|
2001-06-26 |
2009-06-09 |
Biomarck Pharmaceuticals, Ltd. |
Methods for regulating inflammatory mediators and peptides useful therein
|
US8501911B2
(en)
*
|
1999-02-24 |
2013-08-06 |
Biomarck Pharmaceuticals, Ltd |
Methods of reducing inflammation and mucus hypersecretion
|
CA2330022A1
(en)
*
|
1999-04-06 |
2000-10-26 |
East Carolina University |
Low adenosine anti-sense oligonucleotide, compositions, kit and method for treatment of airway disorders associated with bronchoconstriction, lung inflammation, allergy(ies) and surfactant depletion
|
WO2000061184A2
(en)
*
|
1999-04-08 |
2000-10-19 |
Glenn Gregory M |
Dry formulation for transcutaneous immunization
|
AU7595000A
(en)
*
|
1999-09-23 |
2001-04-24 |
General Hospital Corporation, The |
Methods for potentiating antisense rna techniques
|
AU784123B2
(en)
|
1999-10-13 |
2006-02-09 |
Marco A. Chacon |
Therapeutic intervention to mimic the effect of caloric restriction
|
US7115712B1
(en)
|
1999-12-02 |
2006-10-03 |
Maxygen, Inc. |
Cytokine polypeptides
|
US7265088B1
(en)
|
2000-02-24 |
2007-09-04 |
North Carolina State University |
Method and compositions for altering mucus secretion
|
US7919469B2
(en)
|
2000-02-24 |
2011-04-05 |
North Carolina State University |
Methods and compositions for altering mucus secretion
|
US7871598B1
(en)
*
|
2000-05-10 |
2011-01-18 |
Novartis Ag |
Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
|
US8404217B2
(en)
*
|
2000-05-10 |
2013-03-26 |
Novartis Ag |
Formulation for pulmonary administration of antifungal agents, and associated methods of manufacture and use
|
WO2001085136A2
(en)
*
|
2000-05-10 |
2001-11-15 |
Alliance Pharmaceutical Corporation |
Phospholipid-based powders for drug delivery
|
US10293056B1
(en)
*
|
2000-05-24 |
2019-05-21 |
Board Of Regents, The University Of Texas System |
Methods and compositions for non-viral gene therapy for treatment of hyperproliferative diseases
|
US20020106368A1
(en)
*
|
2000-07-28 |
2002-08-08 |
Adrian Bot |
Novel methods and compositions to upregulate, redirect or limit immune responses to peptides, proteins and other bioactive compounds and vectors expressing the same
|
ES2310201T3
(es)
*
|
2001-02-13 |
2009-01-01 |
Government Of The United States Of America, As Represented By The Secretary Of The Army |
Vacuna para inmunizacion transcutanea contra la diarrea de los viajeros.
|
EP1383480A4
(de)
*
|
2001-04-30 |
2006-05-24 |
Targeted Genetics Corp |
Lipidenthaltende arzneimittelabgabe-komplexe und herstellungsverfahren dafür
|
WO2002087541A1
(en)
*
|
2001-04-30 |
2002-11-07 |
Protiva Biotherapeutics Inc. |
Lipid-based formulations for gene transfer
|
CN100384480C
(zh)
*
|
2001-05-30 |
2008-04-30 |
斯克里普斯研究学院 |
核酸传递系统
|
WO2003015707A2
(en)
*
|
2001-08-20 |
2003-02-27 |
Transave, Inc. |
Method for treating lung cancers
|
WO2003015521A1
(en)
*
|
2001-08-20 |
2003-02-27 |
Transave, Inc. |
Treatment of cancers by inhalation of stable platinum-containing formulations
|
US20040076966A1
(en)
*
|
2001-10-30 |
2004-04-22 |
J. Brian Windsor |
Method and system for the co-isolation of cognate DNA, RNA and protein sequences and method for screening co-isolates for defined activities
|
CN100384865C
(zh)
*
|
2001-11-02 |
2008-04-30 |
嵌入治疗公司 |
用于rna干扰的治疗用途的方法及组合物
|
IL161733A0
(en)
|
2001-11-02 |
2005-11-20 |
Insert Therapeutics Inc |
Methods and compositions for therapeutic use of rna interference
|
US20040063654A1
(en)
*
|
2001-11-02 |
2004-04-01 |
Davis Mark E. |
Methods and compositions for therapeutic use of RNA interference
|
AUPR894201A0
(en)
*
|
2001-11-19 |
2001-12-13 |
Women's And Children's Hospital |
Respiratory delivery for gene therapy and lentiviral delivery particle
|
TWI324518B
(en)
|
2001-12-19 |
2010-05-11 |
Nektar Therapeutics |
Pulmonary delivery of aminoglycosides
|
US20040009126A1
(en)
*
|
2002-03-05 |
2004-01-15 |
Transave, Inc. |
Inhalation system for prevention and treatment of intracellular infections
|
WO2004007664A2
(en)
*
|
2002-05-28 |
2004-01-22 |
Maxygen, Inc. |
Nucleic acid vectors
|
EP2338478B1
(de)
|
2002-06-28 |
2014-07-23 |
Protiva Biotherapeutics Inc. |
Verfahren zur Herstellung von Liposomen
|
MXPA05001312A
(es)
*
|
2002-08-02 |
2005-08-03 |
Transave Inc |
Agregados de platino y proceso para producir los mismos.
|
US9186322B2
(en)
*
|
2002-08-02 |
2015-11-17 |
Insmed Incorporated |
Platinum aggregates and process for producing the same
|
US7718189B2
(en)
|
2002-10-29 |
2010-05-18 |
Transave, Inc. |
Sustained release of antiinfectives
|
ES2686361T3
(es)
*
|
2002-10-29 |
2018-10-17 |
Insmed Incorporated |
Liposomas que comprenden un aminoglucósido para el tratamiento de infecciones pulmonares
|
US7879351B2
(en)
*
|
2002-10-29 |
2011-02-01 |
Transave, Inc. |
High delivery rates for lipid based drug formulations, and methods of treatment thereof
|
CN1708724A
(zh)
*
|
2002-11-01 |
2005-12-14 |
科比恩公司 |
多区域垂直排列液晶显示器
|
PT2656854E
(pt)
|
2003-02-04 |
2015-09-03 |
Cornell Res Foundation Inc |
Utilizações de péptido aromático catiónico
|
NZ543410A
(en)
|
2003-05-01 |
2008-07-31 |
Cornell Res Foundation Inc |
Carrier complexes comprising at least one molecule and an aromatic cationic peptide that can cross cell membranes by an energy-independent mechanism and deliver the molecules inside the cell
|
WO2005020885A2
(en)
*
|
2003-05-21 |
2005-03-10 |
Isis Pharmaceuticals, Inc. |
Compositions and methods for the treatment of severe acute respiratory syndrome (sars)
|
AU2003252493A1
(en)
*
|
2003-07-09 |
2005-01-28 |
Anges Mg, Inc. |
Pharmaceutical composition containing decoy and method of using the same
|
EP1648519B1
(de)
|
2003-07-16 |
2014-10-08 |
Protiva Biotherapeutics Inc. |
Lipid verkapselte interferierende rns
|
WO2005023292A1
(en)
|
2003-09-03 |
2005-03-17 |
The General Hospital Corporation |
Methods of treating restenosis
|
KR101164256B1
(ko)
|
2003-09-15 |
2012-07-10 |
프로티바 바이오쎄라퓨틱스, 인코포레이티드 |
폴리에틸렌글리콜 개질된 지질 화합물 및 그의 용도
|
WO2005048935A2
(en)
|
2003-11-14 |
2005-06-02 |
Brigham And Women's Hospital, Inc. |
Methods of modulating immunity
|
CN1914320A
(zh)
*
|
2003-12-03 |
2007-02-14 |
中外制药株式会社 |
利用哺乳类β肌动蛋白启动子的表达体系
|
US8592368B2
(en)
*
|
2003-12-19 |
2013-11-26 |
University Of South Florida |
JAK/STAT inhibitors and MAPK/ERK inhibitors for RSV infection
|
KR101159254B1
(ko)
|
2004-01-23 |
2012-06-26 |
코넬 리서치 화운데이션,인크. |
산화성 손상을 저감하는 방법
|
US20080063700A1
(en)
*
|
2004-01-23 |
2008-03-13 |
Keio University |
Support Accumulating In Injured Part In Vascular Channel
|
WO2005078848A2
(en)
*
|
2004-02-11 |
2005-08-25 |
University Of Tennessee Research Foundation |
Inhibition of tumor growth and invasion by anti-matrix metalloproteinase dnazymes
|
US20050181035A1
(en)
*
|
2004-02-17 |
2005-08-18 |
Dow Steven W. |
Systemic immune activation method using non CpG nucleic acids
|
US20070065522A1
(en)
*
|
2004-03-18 |
2007-03-22 |
Transave, Inc. |
Administration of high potency platinum compound formulations by inhalation
|
CA2559722A1
(en)
*
|
2004-03-18 |
2005-09-29 |
Transave, Inc. |
Administration of cisplatin by inhalation
|
JP2008500397A
(ja)
*
|
2004-05-21 |
2008-01-10 |
トランセイブ, インク. |
肺疾患及び前肺疾患状態の治療
|
AU2005251403B2
(en)
|
2004-06-07 |
2011-09-01 |
Arbutus Biopharma Corporation |
Cationic lipids and methods of use
|
JP4796062B2
(ja)
|
2004-06-07 |
2011-10-19 |
プロチバ バイオセラピューティクス インコーポレイティッド |
脂質封入干渉rna
|
WO2006002538A1
(en)
|
2004-07-02 |
2006-01-12 |
Protiva Biotherapeutics, Inc. |
Immunostimulatory sirna molecules and uses therefor
|
WO2006007712A1
(en)
*
|
2004-07-19 |
2006-01-26 |
Protiva Biotherapeutics, Inc. |
Methods comprising polyethylene glycol-lipid conjugates for delivery of therapeutic agents
|
US20060045849A1
(en)
*
|
2004-08-24 |
2006-03-02 |
Farhan Taghizadeh |
Method of customizing the fragrance of nasal medications
|
EP1811963A4
(de)
*
|
2004-11-08 |
2010-01-06 |
Transave Inc |
Verfahren zur krebsbehandlung mit intraperitoneal verabreichten platinverbindungsformulierungen auf lipidbasis
|
WO2006053430A1
(en)
*
|
2004-11-17 |
2006-05-26 |
Protiva Biotherapeutics, Inc. |
Sirna silencing of apolipoprotein b
|
ZA200706339B
(en)
|
2005-01-20 |
2008-09-25 |
Biomarck Pharmaceuticals Ltd |
Mucin hypertension inhibitors based on the structure of mans and methods of use
|
EP1858542A4
(de)
|
2005-02-24 |
2009-08-19 |
Joslin Diabetes Center Inc |
Zusammensetzungen und verfahren zur behandlung von gefässpermeabilität
|
JP2008537551A
(ja)
|
2005-03-31 |
2008-09-18 |
カランド ファーマシューティカルズ, インコーポレイテッド |
リボヌクレオチドレダクターゼサブユニット2の阻害剤およびその使用
|
UA95446C2
(ru)
|
2005-05-04 |
2011-08-10 |
Іллюміджен Байосайєнсіз, Інк. |
Мутаци в генах oas1
|
US20070031342A1
(en)
*
|
2005-06-22 |
2007-02-08 |
Nektar Therapeutics |
Sustained release microparticles for pulmonary delivery
|
US20110178092A1
(en)
*
|
2005-06-22 |
2011-07-21 |
Akbar Ali |
HIV-1 Protease Inhibitors
|
US20070054873A1
(en)
*
|
2005-08-26 |
2007-03-08 |
Protiva Biotherapeutics, Inc. |
Glucocorticoid modulation of nucleic acid-mediated immune stimulation
|
EP3095454A1
(de)
|
2005-09-16 |
2016-11-23 |
Cornell Research Foundation, Inc. |
Aromatisch-kationisches peptid zur verwendung in einem verfahren zur reduzierung der cd36-expression
|
JP2009513716A
(ja)
*
|
2005-11-01 |
2009-04-02 |
アルナイラム ファーマシューティカルズ インコーポレイテッド |
RNAiによるインフルエンザウイルス複製の抑制
|
EP1948674A4
(de)
|
2005-11-02 |
2009-02-04 |
Protiva Biotherapeutics Inc |
Modifizierte sirna-moleküle und anwendungen davon
|
WO2007056264A2
(en)
*
|
2005-11-08 |
2007-05-18 |
Transave, Inc. |
Methods of treating cancer with high potency lipid-based platinum compound formulations administered intraperitoneally
|
US9107824B2
(en)
|
2005-11-08 |
2015-08-18 |
Insmed Incorporated |
Methods of treating cancer with high potency lipid-based platinum compound formulations administered intraperitoneally
|
CA2896083A1
(en)
|
2005-12-08 |
2007-06-14 |
Insmed Incorporated |
Lipid-based compositions of antiinfectives for treating pulmonary infections and methods of use thereof
|
WO2007092944A2
(en)
*
|
2006-02-08 |
2007-08-16 |
Introgen Therapeutics, Inc. |
Compositions and methods involving gene therapy and proteasome modulation
|
EP1994043A4
(de)
|
2006-02-10 |
2009-05-20 |
Univ Cincinnati |
Phosphatasehemmer-protein 1 als regulator der herzfunktion
|
KR100745833B1
(ko)
|
2006-03-06 |
2007-08-02 |
고려대학교 산학협력단 |
양이온성 골드 나노입자와 유전자의 복합체 조성물
|
EP1993611A4
(de)
*
|
2006-03-16 |
2013-05-22 |
Alnylam Pharmaceuticals Inc |
Rnai-modulation von tgf-beta und ihre therapeutische verwendung
|
WO2007123777A2
(en)
*
|
2006-03-30 |
2007-11-01 |
Duke University |
Inhibition of hif-1 activation for anti-tumor and anti-inflammatory responses
|
WO2007124131A2
(en)
*
|
2006-04-20 |
2007-11-01 |
The University Of North Carolina At Chapel Hill |
Hybrid nanomaterials as multimodal imaging contrast agents
|
US7812150B2
(en)
|
2006-05-19 |
2010-10-12 |
Alnylam Pharmaceuticals, Inc. |
RNAi modulation of Aha and therapeutic uses thereof
|
US7915399B2
(en)
|
2006-06-09 |
2011-03-29 |
Protiva Biotherapeutics, Inc. |
Modified siRNA molecules and uses thereof
|
EP2053915B1
(de)
|
2006-07-26 |
2014-06-11 |
Biomarck Pharmaceuticals, Ltd. |
Peptide zur minderung der freisetzung von entzündungsmediatoren
|
KR100825519B1
(ko)
*
|
2007-01-05 |
2008-04-25 |
주식회사 바이오폴리메드 |
키토산 기재 고분자 접합체 및 그 제조방법
|
US20100196455A1
(en)
*
|
2007-05-04 |
2010-08-05 |
Transave, Inc. |
Compositions of Multicationic Drugs for Reducing Interactions with Polyanionic Biomolecules and Methods of Use Thereof
|
US9333214B2
(en)
|
2007-05-07 |
2016-05-10 |
Insmed Incorporated |
Method for treating pulmonary disorders with liposomal amikacin formulations
|
US9114081B2
(en)
|
2007-05-07 |
2015-08-25 |
Insmed Incorporated |
Methods of treating pulmonary disorders with liposomal amikacin formulations
|
US9119783B2
(en)
|
2007-05-07 |
2015-09-01 |
Insmed Incorporated |
Method of treating pulmonary disorders with liposomal amikacin formulations
|
ES2559859T3
(es)
|
2007-05-16 |
2016-02-16 |
The Brigham And Women's Hospital, Inc. |
Tratamiento de sinucleinopatías
|
EP2902036A1
(de)
|
2008-02-07 |
2015-08-05 |
Cornell University |
Verfahren zur Vorbeugung oder Behandlung von Insulinresistenz
|
US20110135571A1
(en)
*
|
2008-02-22 |
2011-06-09 |
Wenbin Lin |
Hybrid nanoparticles as anti-cancer therapeutic agents and dual therapeutic/imaging contrast agents
|
WO2009108695A2
(en)
|
2008-02-26 |
2009-09-03 |
Cornell University |
Methods for prevention and treatment of acute renal injury
|
JP2011516065A
(ja)
|
2008-04-04 |
2011-05-26 |
カランド ファーマシューティカルズ, インコーポレイテッド |
Epas1阻害剤の組成物および使用
|
WO2009129220A2
(en)
|
2008-04-14 |
2009-10-22 |
The Gereral Hospital Corporation |
Plectin-1 targeted agents for detection and treatment of pancreatic ductal adenocarcinoma
|
DK2279254T3
(en)
|
2008-04-15 |
2017-09-18 |
Protiva Biotherapeutics Inc |
PRESENT UNKNOWN LIPID FORMS FOR NUCLEIC ACID ADMINISTRATION
|
EP2294184A4
(de)
|
2008-06-30 |
2013-03-06 |
Mesoblast Inc |
Behandlung von augenerkrankungen und exzessiver neovaskularisation mithilfe einer kombinierten therapie
|
US20110208064A1
(en)
|
2008-07-31 |
2011-08-25 |
Ran Chongzhao |
Curcumin Derivatives for Amyloid-Beta Plaque Imaging
|
ES2475065T3
(es)
|
2008-10-09 |
2014-07-10 |
Tekmira Pharmaceuticals Corporation |
Aminol�pidos mejorados y métodos para la administración de ácidos nucleicos
|
EP2361098B1
(de)
|
2008-10-31 |
2019-08-28 |
The General Hospital Corporation |
Zusammensetzungen und verfahren zur abgabe einer substanz an ein biologisches target
|
US8889618B2
(en)
|
2008-11-07 |
2014-11-18 |
The General Hospital Corporation |
C-terminal fragments of glucagon-like peptide-1 (GLP-1)
|
TW201031436A
(en)
*
|
2009-02-16 |
2010-09-01 |
Univ Nat Taiwan |
Pharmaceutical composition for inhalation delivery and fabrication method thereof
|
WO2010105096A2
(en)
|
2009-03-11 |
2010-09-16 |
University Of Massachusetts |
Modulation of human cytomegalovirus replication by micro-rna 132 (mir132), micro-rna 145 (mir145) and micro-rna 212 (mir212)
|
JP2012521355A
(ja)
*
|
2009-03-20 |
2012-09-13 |
ザ ジェネラル ホスピタル コーポレイション ディー ビー エイ マサチューセッツ ジェネラル ホスピタル |
熱傷及び二次性合併症の予防及び治療方法
|
JP2010251707A
(ja)
*
|
2009-03-27 |
2010-11-04 |
Fujitsu Ltd |
配線基板及び半導体装置
|
EP2756845B1
(de)
|
2009-04-03 |
2017-03-15 |
Dicerna Pharmaceuticals, Inc. |
Verfahren und Zusammensetzungen für spezifische KRAS-Hemmung mit asymmetrischer Doppelstrang-RNA
|
JP5766188B2
(ja)
|
2009-07-01 |
2015-08-19 |
プロチバ バイオセラピューティクス インコーポレイティッド |
固形腫瘍に治療剤を送達するための脂質製剤
|
US8569256B2
(en)
|
2009-07-01 |
2013-10-29 |
Protiva Biotherapeutics, Inc. |
Cationic lipids and methods for the delivery of therapeutic agents
|
US9018187B2
(en)
|
2009-07-01 |
2015-04-28 |
Protiva Biotherapeutics, Inc. |
Cationic lipids and methods for the delivery of therapeutic agents
|
JP5909182B2
(ja)
|
2009-08-12 |
2016-04-26 |
コーネル ユニヴァーシティー |
代謝性症候群を予防し又は治療するための方法
|
EP3708178B1
(de)
|
2009-08-24 |
2023-10-04 |
Stealth BioTherapeutics Inc. |
Peptid zur verwendung bei der vorbeugung oder behandlung von makula degenerationugenleiden
|
WO2011041385A2
(en)
|
2009-09-29 |
2011-04-07 |
Joslin Diabetes Center, Inc. |
Use of protein kinase c delta (pkcd) inhibitors to treat diabetes, obesity, and hepatic steatosis
|
EP3120860B1
(de)
|
2009-10-05 |
2019-06-26 |
Cornell University |
Verfahren zur prävention und behandlung von herzinsuffizienz
|
AU2010326132B9
(en)
|
2009-12-01 |
2014-10-02 |
Translate Bio, Inc. |
Delivery of mRNA for the augmentation of proteins and enzymes in human genetic diseases
|
EP3100739A1
(de)
|
2009-12-31 |
2016-12-07 |
Stealth Peptides International, Inc. |
Verfahren zur durchführung eines koronararterien-bypass-verfahrens
|
EP2910250A1
(de)
|
2009-12-31 |
2015-08-26 |
Stealth Peptides International, Inc. |
Verfahren zur Vorbeugung oder Behandlung einer Gefäßverschlussverletzung
|
EP3018138A1
(de)
|
2010-01-25 |
2016-05-11 |
Cornell University |
Aromatische-kationische peptide und verwendungen davon
|
US9757448B2
(en)
|
2010-02-26 |
2017-09-12 |
The Brigham And Women's Hospital, Inc. |
Methods of treating cerebral amyloid angiopathy
|
EP3560508A1
(de)
|
2010-03-15 |
2019-10-30 |
Stealth Peptides International, Inc. |
Kombinationstherapien mit verwendung von cyclosporin und aromatischen kationischen peptiden
|
KR20130066626A
(ko)
|
2010-04-29 |
2013-06-20 |
나스벡스 엘티디. |
항cd3 면역 분자 요법을 사용하여 간염을 치료하는 방법 및 이를 위한 조성물
|
WO2011139992A1
(en)
|
2010-05-03 |
2011-11-10 |
Stealth Peptides International, Inc. |
Aromatic-cationic peptides and uses of same
|
WO2012000104A1
(en)
|
2010-06-30 |
2012-01-05 |
Protiva Biotherapeutics, Inc. |
Non-liposomal systems for nucleic acid delivery
|
CN107569675A
(zh)
|
2010-07-09 |
2018-01-12 |
康德生物医疗技术公司 |
预防或治疗缺血/再灌注损伤之后无复流的方法
|
WO2012050673A1
(en)
|
2010-10-14 |
2012-04-19 |
Wisconsin Alumni Research Foundation |
Methods for the treatment of x-linked hypophosphatemia and related disorders
|
WO2012054718A2
(en)
|
2010-10-22 |
2012-04-26 |
The General Hospital Corporation |
Treating long qt syndrome
|
WO2012065182A2
(en)
|
2010-11-12 |
2012-05-18 |
University Of Massachusetts |
Modulation of ubiquitination of synaptic proteins for the treatment of neurodegenerative and psychiatric disorders
|
EP3211001B1
(de)
|
2010-12-22 |
2020-10-07 |
The Board of Trustees of the Leland Stanford Junior University |
Superagonisten und antagonisten von interleukin-2
|
CN109705192A
(zh)
|
2011-03-24 |
2019-05-03 |
康奈尔大学 |
芳香族阳离子肽及其用途
|
US20140112898A1
(en)
|
2011-03-31 |
2014-04-24 |
President And Fellows Of Harvard College |
Unique population of regulatory t cells that regulate tissue regeneration and wound healing
|
EP2729157B1
(de)
|
2011-07-06 |
2019-01-16 |
The General Hospital Corporation |
Ein pentapeptid aus dem c-terminus des glucagon-like peptids-1 (glp-1) zur verwendung in der behandlung
|
EP3494974B1
(de)
|
2011-07-08 |
2023-10-18 |
The University of North Carolina at Chapel Hill |
Metall-bisphosphonat-nanopartikel zur krebstherapie sowie bildgebung und zur behandlung von knochenerkrankungen
|
CN107496899A
(zh)
|
2011-09-29 |
2017-12-22 |
梅约医学教育与研究基金会 |
芳族阳离子肽和使用它们的方法
|
GB201118704D0
(en)
*
|
2011-10-28 |
2011-12-14 |
Univ Oxford |
Cystic fibrosis treatment
|
WO2013075132A1
(en)
|
2011-11-17 |
2013-05-23 |
The United States Of America, As Represented By The Secretary, Department Of Health & Human Services |
Therapeutic rna switches compositions and methods of use
|
US20140294796A1
(en)
|
2011-12-09 |
2014-10-02 |
D. Travis Wilson |
Aromatic-cationic peptides and uses of same
|
WO2013126597A1
(en)
|
2012-02-22 |
2013-08-29 |
Stealth Peptides International, Inc. |
Methods and compositions for preventing or treating ophthalmic conditions
|
EP3513800B1
(de)
|
2012-02-23 |
2022-12-07 |
Cornell University |
Aromatisches-kationisches peptide zur verwendung in der behandlung des antiphospholipid-syndroms
|
US9603897B2
(en)
|
2012-03-12 |
2017-03-28 |
Massachusetts Institute Of Technology |
Methods for treating tissue damage associated with ischemia with apolipoprotein D
|
WO2013155447A1
(en)
|
2012-04-13 |
2013-10-17 |
Children's Medical Center Corporation |
Tiki inhibitors
|
CA2870860C
(en)
|
2012-05-21 |
2021-07-27 |
Insmed Incorporated |
Systems for treating pulmonary infections
|
JP6561378B2
(ja)
*
|
2012-06-08 |
2019-08-21 |
トランスレイト バイオ, インコーポレイテッド |
非肺標的細胞へのmRNAの経肺送達
|
CA2880648A1
(en)
|
2012-08-02 |
2014-02-06 |
Stealth Peptides International, Inc. |
Methods for treatment of atherosclerosis
|
US9738623B2
(en)
|
2012-08-06 |
2017-08-22 |
The General Hospital Corporation |
Curcumin analogs
|
ES2848025T3
(es)
|
2012-09-04 |
2021-08-05 |
Eleison Pharmaceuticals LLC |
Prevención de la recidiva pulmonar del cáncer con cisplatino complejado con lípidos
|
EP4005582A1
(de)
|
2012-10-22 |
2022-06-01 |
Stealth BioTherapeutics Inc. |
Behandlung von linksventrikulärer remodellierung
|
US9902705B2
(en)
|
2012-10-24 |
2018-02-27 |
The General Hospital Corporation |
Functionalized 1,2,4,5-tetrazine compounds for use in bioorthogonal coupling reactions
|
RU2675859C2
(ru)
|
2012-11-29 |
2018-12-25 |
Инсмед Инкорпорейтед |
Стабилизированные составы ванкомицина
|
EP3287172A1
(de)
|
2012-12-06 |
2018-02-28 |
Stealth Peptides International, Inc. |
Zusammenfassungen von peptidtherapeutischen wirkstoffen und verfahren zur verwendung davon
|
EP3789022A1
(de)
|
2012-12-27 |
2021-03-10 |
Massachusetts Eye & Ear Infirmary |
Behandlung von rhinosinusitis mit p-glycoprotein-hemmern
|
JP6526570B2
(ja)
|
2013-01-11 |
2019-06-12 |
マサチューセッツ アイ アンド イヤー インファーマリー |
炎症及び血管形成を減少させるcyp450脂質メタボライト
|
WO2014128257A1
(en)
|
2013-02-22 |
2014-08-28 |
Sanofi |
Serpins: methods of therapeutic beta-cell regeneration and function
|
EP2851086A1
(de)
|
2013-09-20 |
2015-03-25 |
Sanofi |
Serpine: Verfahren zur therapeutischen ß-Zellen-Regeneration und Funktion
|
EP2769732A1
(de)
|
2013-02-22 |
2014-08-27 |
Sanofi |
Serpine: Verfahren zur therapeutischen Beta-Zellen-Regeneration und Funktion
|
EP2961420B1
(de)
|
2013-03-01 |
2019-09-11 |
Stealth Biotherapeutics Corp |
Verfahren und zusammensetzungen zur prävention oder behandlung des barth-syndroms
|
DK2961378T3
(da)
|
2013-03-01 |
2019-11-25 |
Stealth Biotherapeutics Corp |
Fremgangsmåder til behandlingen af mitochondrisk sygdom
|
US9981038B2
(en)
|
2013-03-13 |
2018-05-29 |
The General Hospital Corporation |
Photoswitchable HDAC inhibitors
|
US9757468B2
(en)
|
2013-03-13 |
2017-09-12 |
The Regents Of The University Of California |
Intranasal administration of guanidinylated aminoglycosides
|
AR095426A1
(es)
|
2013-03-14 |
2015-10-14 |
Onyx Therapeutics Inc |
Inhibidores tripeptídicos de la epoxicetona proteasa
|
KR20150131276A
(ko)
|
2013-03-14 |
2015-11-24 |
오닉스 세라퓨틱스, 인크. |
디펩타이드 및 트리펩타이드 에폭시 케톤 프로테이스 억제제
|
SG11201507366RA
(en)
|
2013-03-15 |
2015-10-29 |
Gen Hospital Corp |
Glycine, mitochondrial one-carbon metabolism, and cancer
|
JP2016522196A
(ja)
|
2013-05-14 |
2016-07-28 |
ステルス バイオセラピューティックス コープ |
左室リモデリングの予防または治療のための方法
|
WO2014197818A2
(en)
|
2013-06-07 |
2014-12-11 |
The General Hospital Corporation |
Small molecule activators of nrf2 pathway
|
US10047395B2
(en)
|
2013-06-26 |
2018-08-14 |
Stealth Biotherapeutics Corp |
Methods and compositions for detecting and diagnosing diseases and conditions
|
US9884085B2
(en)
|
2013-06-26 |
2018-02-06 |
Stealth Biotherapeutics Corp |
Methods for the regulation of matrix metalloproteinase expression
|
WO2015009414A1
(en)
|
2013-06-26 |
2015-01-22 |
Stealth Peptides International, Inc. |
Methods and compositions for regulating srca2a expression levels in myocardial infarction
|
US10293020B2
(en)
|
2013-06-27 |
2019-05-21 |
Stealth Biotherapeutics Corp. |
Peptide therapeutics and methods for using same
|
CA2920020C
(en)
|
2013-08-02 |
2023-03-14 |
Stealth Biotherapeutics Corp |
Methods and compositions for the prevention and treatment of friedreich's ataxia
|
US9757477B2
(en)
|
2013-09-06 |
2017-09-12 |
The General Hospital Corporation |
Imaging brown adipose tissue with curcumin derivatives
|
CA2925421C
(en)
|
2013-09-24 |
2023-08-29 |
Medicenna Therapeutics, Inc. |
Interleukin-2 fusion proteins and uses thereof
|
US10517822B2
(en)
|
2013-11-06 |
2019-12-31 |
The University Of Chicago |
Nanoscale carriers for the delivery or co-delivery of chemotherapeutics, nucleic acids and photosensitizers
|
JP2016540762A
(ja)
|
2013-12-02 |
2016-12-28 |
ステルス バイオセラピューティックス コープ |
白斑の治療のための組成物及び方法
|
WO2015103643A2
(en)
|
2014-01-06 |
2015-07-09 |
The General Hospital Corporation |
Integrin antagonists
|
US10300070B2
(en)
|
2014-03-27 |
2019-05-28 |
The Brigham And Women's Hospital, Inc. |
Metabolically-activated drug conjugates to overcome resistance in cancer therapy
|
WO2015164815A1
(en)
|
2014-04-24 |
2015-10-29 |
The Board Of Trustees Of The Leland Stanford Junior University |
Superagonists, partial agonists and antagonists of interleukin-2
|
ES2926985T3
(es)
|
2014-05-15 |
2022-10-31 |
Insmed Inc |
Métodos para tratar infecciones pulmonares micobacterianas no tuberculosas
|
WO2015175846A2
(en)
|
2014-05-16 |
2015-11-19 |
University Of Massachusetts |
Treating chronic myelogenous leukemia (cml)
|
EP3501532A3
(de)
|
2014-05-28 |
2019-07-17 |
Stealth BioTherapeutics Corp |
Therapeutische zusammensetzungen mit frataxin, lactoferrin, sowie mitochondrialen energieerzeugungsenzymen und verwendungen davon
|
US20170182117A1
(en)
|
2014-05-28 |
2017-06-29 |
Stealth Biotherapeutics Corp |
Therapeutic compositions including therapeutic
small molecules and uses thereof
|
CN106536056B
(zh)
|
2014-06-13 |
2021-07-16 |
儿童医学中心公司 |
分离线粒体的产品和方法
|
US10627392B2
(en)
|
2014-06-17 |
2020-04-21 |
Stealth Biotherapeutics Corp |
Methods of identifying and monitoring mitochondrial dysfunction using monocyte screening
|
CN106572974B
(zh)
|
2014-07-15 |
2021-04-23 |
生命技术公司 |
用于将分子有效递送到细胞的具有脂质聚集体的组合物和方法
|
WO2016025480A1
(en)
|
2014-08-11 |
2016-02-18 |
The General Hospital Corporation |
Cyclooctenes for bioorthogonol reactions
|
CN107106637B
(zh)
|
2014-08-21 |
2021-06-25 |
康德生物医疗技术公司 |
用于疾病预防和治疗的方法和组合物
|
JO3474B1
(ar)
|
2014-08-29 |
2020-07-05 |
Amgen Inc |
مشتقات تيتراهيدرونافثالين التي تثبط بروتين mcl-1
|
MA42161A
(fr)
|
2014-10-14 |
2017-08-23 |
Univ Chicago |
Nanoparticules pour thérapie photodynamique, thérapie photodynamique induite par rayons x, radiothérapie, chimiothérapie, immunothérapie, et toute combinaison de celles-ci
|
US10806694B2
(en)
|
2014-10-14 |
2020-10-20 |
The University Of Chicago |
Nanoparticles for photodynamic therapy, X-ray induced photodynamic therapy, radiotherapy, radiodynamic therapy, chemotherapy, immunotherapy, and any combination thereof
|
AU2015346657B9
(en)
|
2014-11-10 |
2020-01-16 |
Evrys Bio, Llc |
Anti-HCMV compositions and methods
|
EP3218356B1
(de)
|
2014-11-10 |
2022-11-30 |
Evrys Bio, LLC |
Anti-hcmv-zusammensetzungen und -verfahren
|
US10420826B2
(en)
|
2014-11-11 |
2019-09-24 |
Massachusetts Eye & Ear Infirmary |
Conjunctivitis vaccines
|
JP7105065B2
(ja)
|
2014-12-15 |
2022-07-22 |
ダイセルナ ファーマシューティカルズ, インコーポレイテッド |
リガンド修飾二本鎖核酸
|
CA2973585A1
(en)
|
2015-01-12 |
2016-07-21 |
Children's Medical Center Corporation |
Pro-inflammatory and adjuvant functions of toll-like receptor 4 antagonists
|
US20170151281A1
(en)
|
2015-02-19 |
2017-06-01 |
Batu Biologics, Inc. |
Chimeric antigen receptor dendritic cell (car-dc) for treatment of cancer
|
WO2016164642A1
(en)
|
2015-04-08 |
2016-10-13 |
The United States Of America, As Represented By The Secretary Of Health And Human Services |
Viral gene therapy as treatment for cholesterol storage disease or disorder
|
EP3292206B8
(de)
|
2015-05-07 |
2022-02-09 |
Takeda Pharmaceutical Company Limited |
Glucocerebrosidase gentherapie von morbus parkinson
|
WO2016193945A2
(en)
|
2015-06-05 |
2016-12-08 |
Novartis Ag |
Methods and compositions for diagnosing, treating, and monitoring treatment of shank3 deficiency associated disorders
|
US10000561B2
(en)
|
2015-09-09 |
2018-06-19 |
Novartis Ag |
Thymic stromal lymphopoietin (TSLP)-binding molecules and methods of using the molecules
|
CA2996635A1
(en)
|
2015-09-09 |
2017-03-16 |
Novartis Ag |
Thymic stromal lymphopoietin (tslp)-binding molecules and methods of using the molecules
|
US10449259B2
(en)
|
2015-10-02 |
2019-10-22 |
Cornell University |
Enzyme-responsive peptide nanofiber compositions and uses thereof
|
WO2017066712A2
(en)
|
2015-10-16 |
2017-04-20 |
The Children's Medical Center Corporation |
Modulators of telomere disease
|
AU2016355178B9
(en)
|
2015-11-19 |
2019-05-30 |
Massachusetts Institute Of Technology |
Lymphocyte antigen CD5-like (CD5L)-interleukin 12B (p40) heterodimers in immunity
|
JOP20200228A1
(ar)
|
2015-12-21 |
2017-06-16 |
Novartis Ag |
تركيبات وطرق لخفض تعبير البروتين tau
|
EP4085920A1
(de)
|
2016-01-06 |
2022-11-09 |
Stealth BioTherapeutics Inc. |
Verfahren zur behandlung von duchenne-muskeldystrophie
|
WO2017123933A1
(en)
|
2016-01-15 |
2017-07-20 |
Massachusetts Eye And Ear Infirmary |
Secreted p-glycoprotein is a non-invasive biomarker of chronic rhinosinusitis
|
WO2017147410A1
(en)
|
2016-02-25 |
2017-08-31 |
Amgen Inc. |
Compounds that inhibit mcl-1 protein
|
EP3458159A4
(de)
|
2016-05-19 |
2019-12-18 |
Stealth BioTherapeutics Corp |
Zusammensetzungen und verfahren zur prävention und behandlung von mitochondrialen myopathien
|
JP7090034B2
(ja)
|
2016-05-20 |
2022-06-23 |
ザ ユニバーシティ オブ シカゴ |
化学療法、標的療法、光線力学療法、免疫療法及びそれらの任意の組み合わせのためのナノ粒子
|
WO2017218355A1
(en)
|
2016-06-15 |
2017-12-21 |
Counterpoint Biomedica Llc |
Polypeptide targeting aptamers for characterization, capture, and clinical management of circulating tumor cells
|
US10449230B2
(en)
|
2016-10-06 |
2019-10-22 |
The Regents Of The University Of California |
Polymyxin derived cell penetrating scaffolds
|
WO2018089688A1
(en)
|
2016-11-09 |
2018-05-17 |
Jinjun Shi |
Restoration of tumor suppression using mrna-based delivery system
|
CN109996809A
(zh)
|
2016-11-14 |
2019-07-09 |
诺华股份有限公司 |
与促融合蛋白minion相关的组合物、方法和治疗用途
|
US20200054660A1
(en)
|
2016-12-09 |
2020-02-20 |
St. Jude Children's Research Hospital |
Dna methylation profiling for t-cell immunotherapy
|
HUE055417T2
(hu)
|
2016-12-09 |
2021-11-29 |
Akston Biosciences Corp |
Inzulin-Fc fúziók és alkalmazási eljárások
|
US10913779B2
(en)
|
2017-01-25 |
2021-02-09 |
Counterpoint Biomedica Llc |
Exposed collagen-targeted fusion cytokine for immune modulation in invasive cancers and lesions of infections
|
JP6453507B2
(ja)
|
2017-03-30 |
2019-01-16 |
アムジエン・インコーポレーテツド |
Mcl−1タンパク質を阻害する化合物
|
CN111201035A
(zh)
|
2017-06-19 |
2020-05-26 |
梅迪塞纳医疗股份有限公司 |
Il-2超激动剂、激动剂及其融合体的用途和方法
|
CA3068010A1
(en)
|
2017-06-20 |
2018-12-27 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Codon-optimized human npc1 genes for the treatment of niemann-pick type c1 deficiency and related conditions
|
EP3644964B1
(de)
|
2017-06-28 |
2024-04-10 |
Children's Medical Center Corporation |
Förderung des lungenwachstums
|
CN110945018A
(zh)
|
2017-07-27 |
2020-03-31 |
诺华股份有限公司 |
抗脱落酶的trem2变体
|
BR102017016440A2
(pt)
*
|
2017-07-31 |
2019-03-19 |
Universidade Federal Do Rio Grande Do Sul |
Composição para terapia gênica do sistema nervoso central, processo de obtenção e uso da mesma
|
CN111194232B
(zh)
|
2017-08-02 |
2023-01-31 |
芝加哥大学 |
纳米级金属有机层和金属有机纳米片
|
WO2019032717A1
(en)
|
2017-08-08 |
2019-02-14 |
Memorial Sloan Kettering Cancer Center |
USE OF BRAF INHIBITORS FOR TREATING SKIN REACTIONS CAUSED BY TREATMENT WITH MEK INHIBITOR
|
WO2019033114A1
(en)
|
2017-08-11 |
2019-02-14 |
Dana-Farber Cancer Institute, Inc. |
USE OF BOTULINUM TOXIN AGENT FOR THE TREATMENT OF PLASMOCYTE DISORDERS
|
US11821003B2
(en)
|
2017-08-14 |
2023-11-21 |
Sanford Burnham Prebys Medical Discovery Institute |
Cardiogenic mesoderm formation regulators
|
US11364248B2
(en)
|
2017-08-18 |
2022-06-21 |
Amgen Inc. |
Compounds that inhibit Mcl-1 protein
|
WO2019046150A1
(en)
|
2017-08-29 |
2019-03-07 |
Amgen Inc. |
MACROCYCLIC COMPOUNDS FOR INHIBITING MCL-1 PROTEIN
|
WO2019046668A1
(en)
|
2017-08-31 |
2019-03-07 |
Kezar Life Sciences |
AMIDE-SUBSTITUTED THIAZOLES AS INHIBITORS OF SECRETIC PROTEIN
|
WO2019079519A1
(en)
|
2017-10-18 |
2019-04-25 |
Forge Life Science, Llc |
BROAD SPECTRUM ANTIVIRAL COMPOSITIONS AND METHODS
|
WO2019126041A1
(en)
|
2017-12-18 |
2019-06-27 |
The General Hospital Corporation |
Glycoengineering
|
WO2019143969A1
(en)
|
2018-01-18 |
2019-07-25 |
Claudio Maldonado |
Treating microvascular dysfunction
|
US20210363587A1
(en)
|
2018-02-07 |
2021-11-25 |
St. Jude Children's Research Hospital |
EPIGENETIC HISTONE REGULATION MEDIATED BY CXorf67
|
WO2019169202A1
(en)
|
2018-02-28 |
2019-09-06 |
The Johns Hopkins University |
Bacterial biofilms and cancer
|
WO2019173181A1
(en)
|
2018-03-05 |
2019-09-12 |
Amgen Inc. |
Alpha-hydroxy phenylacetic acid pharmacophore or bioisostere mcl-1 protein antagonists
|
WO2019191627A1
(en)
|
2018-03-30 |
2019-10-03 |
Insmed Incorporated |
Methods for continuous manufacture of liposomal drug products
|
US20190314324A1
(en)
|
2018-04-13 |
2019-10-17 |
The University Of Chicago |
Combination of micheliolide derivatives or nanoparticles with ionizing radiation and checkpoint inhibitors for cancer therapy
|
WO2019215333A1
(en)
|
2018-05-11 |
2019-11-14 |
Alpha Anomeric Sas |
Oligonucleotides conjugates comprising 7'-5'-alpha-anomeric-bicyclic sugar nucleosides
|
WO2019238816A1
(en)
|
2018-06-13 |
2019-12-19 |
University Of Dundee |
Bifunctional molecules for targeting uchl5
|
US11925690B2
(en)
|
2018-06-13 |
2024-03-12 |
Amphista Therapeutics Limited |
Bifunctional molecules for targeting Rpn11
|
WO2019238886A1
(en)
|
2018-06-13 |
2019-12-19 |
University Of Dundee |
Bifunctional molecules for targeting usp14
|
WO2020012331A1
(en)
|
2018-07-09 |
2020-01-16 |
St. Jude Children's Research Hospital |
Use of il-12 to alter epigenetic effector programs in cd8 t cells
|
WO2020023806A1
(en)
|
2018-07-25 |
2020-01-30 |
The Johns Hopkins University |
Compositions and methods for generation of heart field-specific progenitor cells
|
US20210292766A1
(en)
|
2018-08-29 |
2021-09-23 |
University Of Massachusetts |
Inhibition of Protein Kinases to Treat Friedreich Ataxia
|
UY38407A
(es)
|
2018-10-15 |
2020-05-29 |
Novartis Ag |
Anticuerpos estabilizadores de trem2
|
DK3866799T3
(da)
|
2018-10-16 |
2024-02-05 |
Univ Johns Hopkins |
Sammensætninger til behandling af vaskulært ehlers-danlos syndrom
|
EP3876977A1
(de)
|
2018-11-06 |
2021-09-15 |
The Regents Of The University Of California |
Chimäre antigen-rezeptoren für phagocytose
|
AU2019392670A1
(en)
|
2018-12-06 |
2021-07-01 |
Stealth Biotherapeutics Inc. |
Methods and compositions for the treatment of Sengers syndrome
|
US20220136051A1
(en)
|
2019-02-22 |
2022-05-05 |
St. Jude Children's Research Hospital |
Methods for identifying and improving t cell multipotency
|
CN113993587A
(zh)
|
2019-02-28 |
2022-01-28 |
科智生命科学公司 |
作为蛋白分泌抑制剂的噻唑衍生物
|
EP3955902A4
(de)
|
2019-04-15 |
2023-03-22 |
Children's Medical Center Corporation |
Aerosolierte zusammensetzungen mit mitochondrien und verfahren zu deren verwendung
|
WO2020237491A1
(en)
|
2019-05-28 |
2020-12-03 |
Shanghaitech University |
Composition and methods to treat ectodermal dysplasia 2, clouston type
|
CN114466656A
(zh)
|
2019-07-24 |
2022-05-10 |
康德生物医疗有限公司 |
在治疗神经变性病症中的模拟肽化合物(r)-2-氨基-n-((s)-1-(((s)-5-氨基-1-(3-苄基-1,2,4-噁二唑-5-基)戊基)氨基)-3-(4-羟基-2,6-二甲苯基)-1-氧代丙-2-基)-5-胍基戊酰胺
|
CA3156499A1
(en)
|
2019-10-04 |
2021-04-08 |
Stealth Biotherapeutics Inc. |
CHINONE, HYDROCHINONE AND NAPHTOCHINONE ANALOGS OF VATIQUINONE FOR THE TREATMENT OF DISEASES WITH MITOCHONDRIAL DISORDERS
|
EP4045525A1
(de)
|
2019-10-17 |
2022-08-24 |
Stridebio, Inc. |
Adeno-assoziierte virusvektoren zur behandlung der niemann-pick-krankheit vom typ c
|
US11491205B2
(en)
|
2020-01-14 |
2022-11-08 |
Synthekine, Inc. |
Biased IL2 muteins methods and compositions
|
US20230076768A1
(en)
|
2020-01-14 |
2023-03-09 |
Synthekine, Inc. |
IL2 Orthologs and Methods of Use
|
TW202140550A
(zh)
|
2020-01-29 |
2021-11-01 |
瑞士商諾華公司 |
使用抗tslp抗體治療炎性或阻塞性氣道疾病之方法
|
WO2021202986A1
(en)
|
2020-04-03 |
2021-10-07 |
Stealth Biotherapeutics Corp |
Compositions and methods for the prevention and/or treatment of mitochondrial disease, including friedreich's ataxia
|
JP2023522933A
(ja)
|
2020-04-23 |
2023-06-01 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
遺伝子操作された食細胞、並びに関連する組成物、ベクター、方法、及びシステム
|
CA3185105A1
(en)
|
2020-07-30 |
2022-02-03 |
Kunwar Shailubhai |
Cd-3 antibodies for the treatment of coronavirus
|
JP2023537005A
(ja)
|
2020-08-05 |
2023-08-30 |
シンセカイン インコーポレイテッド |
Il10受容体結合性分子および使用方法
|
EP4192863A2
(de)
|
2020-08-05 |
2023-06-14 |
Synthekine, Inc. |
Il2rg-bindende moleküle und verfahren zur verwendung
|
IL300736A
(en)
|
2020-08-31 |
2023-04-01 |
Kezar Life Sciences |
Protein secretion inhibitors
|
AU2021376354A1
(en)
|
2020-11-04 |
2023-06-22 |
Myeloid Therapeutics, Inc. |
Engineered chimeric fusion protein compositions and methods of use thereof
|
CA3200234A1
(en)
|
2020-11-25 |
2022-06-02 |
Daryl C. Drummond |
Lipid nanoparticles for delivery of nucleic acids, and related methods of use
|
AU2022220611A1
(en)
|
2021-02-09 |
2023-08-24 |
University Of Georgia Research Foundation, Inc. |
Human monoclonal antibodies against pneumococcal antigens
|
WO2023064942A1
(en)
|
2021-10-14 |
2023-04-20 |
Tiziana Life Sciences Plc |
Methods of suppressing microglial activation
|
WO2023069255A1
(en)
|
2021-10-20 |
2023-04-27 |
Stealth Biotherapeutics Inc. |
Methods and compositions comprising peptidomimitics for treating, preventing, inhibiting, ameliorating or delaying the onset of ophthalmic conditions
|
WO2023101963A2
(en)
|
2021-11-30 |
2023-06-08 |
Northwestern University |
Compositions for inhibiting dipeptide repeat protein-ribosomal rna interaction and uses thereof
|
WO2023133321A1
(en)
|
2022-01-10 |
2023-07-13 |
Stealth Biotherapeutics Inc. |
Small molecule peptidomimetic for the treatment of tauopathies
|
WO2023164250A1
(en)
|
2022-02-28 |
2023-08-31 |
Kezar Life Sciences |
Sec61 inhibitors and use thereof
|
WO2023198757A1
(en)
|
2022-04-14 |
2023-10-19 |
Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. |
Alpha-1-antitrypsin for treating paramyxoviridae or orthomyxoviridae infections
|
GB202214445D0
(en)
*
|
2022-09-30 |
2022-11-16 |
Imp College Innovations Ltd |
Gene therapy
|